India Revokes Roche Patent
BANGALORE—In the latest blow to multinational drug companies, a government board in India has revoked the patent of Roche Holding AG's expensive drug for an infectious liver disease.
The decision Friday by the Intellectual Property Appellate Board to deny patent protection to the hepatitis C drug Pegasys, comes as multinational drug companies here are reeling from denials of patent protection for several expensive therapies that have been granted intellectual-property rights elsewhere in the world.
Novartis AG is currently battling for patent protection for its blockbuster cancer drug Glivec in India's Supreme Court.
The denials of patents on some of the ..
0 comments:
Post a Comment